BridgeBio Awaits FDA Decision
I denne episoden
- BridgeBio Awaits FDA Decision
- Summit Attracts Cancer Partners
- Octane And Currus Automate CAR T
- Tiziana Reports Mixed MS Data
- Biohaven And ArriVent Swing
- Saudi Biotech Builds Resilience
Kilder
- BioSpace: BridgeBio gears up for rare muscular dystrophy launch with FDA approval in sight
- BioSpace: Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
- Pharmatimes: Octane and Currus automate CAR T manufacturing on Cocoon
- BioSpace: Tiziana touts multiple sclerosis win at lower dose as high dose misses mark
- BioSpace: Significant stock movers of October: Biohaven climbs, ArriVent dives
- BioSpace: Can Saudi Arabia's burgeoning biotech hub withstand geopolitical pressures?
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.